Zacks Research Issues Negative Estimate for Novavax Earnings

Novavax, Inc. (NASDAQ:NVAX) – Analysts at Zacks Research lowered their Q1 2025 EPS estimates for Novavax in a report released on Monday, April 14th. Zacks Research analyst S. Ganoria now expects that the biopharmaceutical company will post earnings of ($0.43) per share for the quarter, down from their previous estimate of ($0.42). The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share. Zacks Research also issued estimates for Novavax’s FY2025 earnings at ($0.48) EPS, Q1 2026 earnings at ($0.13) EPS and Q3 2026 earnings at ($0.10) EPS.

Other equities research analysts have also issued reports about the company. TD Cowen upgraded Novavax to a “hold” rating in a research report on Thursday, February 27th. BTIG Research began coverage on shares of Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $18.00.

Novavax Stock Down 3.2 %

Shares of NASDAQ:NVAX opened at $6.00 on Thursday. The company has a market cap of $965.06 million, a P/E ratio of -2.65, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15. The company’s fifty day moving average is $7.27 and its two-hundred day moving average is $8.63. Novavax has a 12-month low of $3.86 and a 12-month high of $23.86.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to analysts’ expectations of $85.48 million. During the same period in the prior year, the business posted ($1.44) EPS.

Hedge Funds Weigh In On Novavax

Several hedge funds have recently bought and sold shares of NVAX. Vanguard Group Inc. raised its stake in shares of Novavax by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company’s stock valued at $126,439,000 after acquiring an additional 296,181 shares in the last quarter. Shah Capital Management boosted its holdings in shares of Novavax by 13.6% during the 4th quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after buying an additional 1,333,305 shares during the period. Sanofi acquired a new position in Novavax in the 4th quarter valued at $55,319,000. Geode Capital Management LLC lifted its position in Novavax by 4.4% during the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company’s stock worth $29,415,000 after acquiring an additional 155,206 shares during the last quarter. Finally, Deep Track Capital LP bought a new stake in Novavax during the fourth quarter valued at about $16,080,000. 53.04% of the stock is owned by institutional investors and hedge funds.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.